UCB Receives Complete Response Letter from U.S. FDA Regarding Neupro (Rotigotine)
"FDA agrees that the proposed new refrigeration conditions significantly inhibit the degree of crystallization on the patches, but has recommended that the definitive resolution of the crystallization is to reformulate the drug product," said Prof. Dr. Iris Loew-Friedrich, Executive Vice President and Chief Medical Officer of UCB. "This FDA decision does not impact product supply and availability in Europe and the rest of the world. It does not change previous assessments made by the European and other international authorities regarding the cold chain storage process."
More than 50 000 patients are being treated by Neupro® in Europe. In the U.S., a Patient Access Program is ongoing and UCB will continue this program.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.